UCB4594
Phase 2Small molecule
UCB4594 is one of 38 small molecule programs targeting Advanced Cancer. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
52 competitors in Advanced Cancer
#DrugCompanyPhaseTrials
1Taxol
TevaPhase 2
Keytruda
Merck & Co.Phase 2
Opdivo
Bristol-Myers SquibbPhase 2
T-Dxd
Daiichi SankyoPhase 3
Verzenio
Eli LillyPhase 2
Herceptin
RochePhase 2
Elunate
TakedaPhase 2
Paraplatin
AAvyxa
Phase 2
Torisel
PPrism Pharmaceuticals
Phase 2
Alimta
SShawn Eagle
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for UCB4594. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- CCancer Research UK